Developing novel lung cancer therapy targetting cancer cell intrinsic ligands

• Project/Area Number: 15K09220
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Osaka University
• Principal Investigator: Kijima Takashi 大阪大学, 医学系研究科, 招へい教授 (90372614)
• Co-Investigator(Kenkyū-buntansha): 南 俊行 大阪大学, 医学系研究科, 特任助教(常勤) (00705113) ; 小山 正平 大阪大学, 免疫学フロンティア研究センター, 特任助教(常勤) (80767559) ; 長 彰翁 大阪大学, 医学部附属病院, 医員 (20751390) ; 森村 治 大阪大学, 医学部附属病院, 医員 (80743765) ; 内藤 祐二朗 大阪大学, 医学部附属病院, 医員 (30800982)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000); Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 肺癌 / 癌微小環境 / 内在性リガンド / アポトーシス小体 / 無菌的炎症誘導 / 化学療法抵抗性 / Toll様受容体 / 微小環境 / 無菌的炎症 / 腫瘍関連マクロファージ / 腫瘍関連線維芽細胞 / MyD88 / 内在性リガント

Outline of Final Research Achievements

In this study, we evaluated how tumor-associated vesicles like apoptotic bodies released after chemotherapies can modulate tumor microenvironment in terms of sensitivity to subsequent chemotherapies. We found that a specific type of chemotherapy can induce TLR2 ligand, which modulate inflammatory status in lung cancer microenvironment and reduce the sensitivity for the subsequent chemotherapies.

Research Products

• [Presentation] Monitoring Nivolumab Binding as a Method to Clarify the Residual Therapeutic Effects in Previously Treated Lung Cancer Patients. (2017)
  • Author(s): A. Osa, S. Koyama, T. Uenami, K. Fujimoto, Y. Naito, H. Hirata, T. Takimoto, I. Nagatomo, Y. Takeda, H. Kida, M. Mori, T. Kijima, A. Kumanogoh
  • Organizer: World Conference on Lung Cancer, Oct 2017
  • Int'l Joint Research